SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust ($SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new record highs in Shanghai and upcoming Chinese export restrictions. This surge is further fueled by critical industrial demand from AI data centers and green energy, prompting community discussion of a potential "silver squeeze" and a significant re-rating of silver's value, though some anticipate a near-term pullback after its rapid ascent.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending due to the FDA's recent approval of YARTEMLEA, its first-in-class treatment for transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening condition with no prior approved therapies. The community is actively discussing the stock's perceived undervaluation, potential for a short squeeze given high short interest, and the significant financial backing from its existing multi-billion dollar partnership with Novo Nordisk. Investors anticipate further clarity on drug pricing and commercial strategy, reinforcing conviction for a substantial long-term re-rating.

ProShares Trust - ProShares UltraShort Silver -2x Shares

ProShares UltraShort Silver

ProShares UltraShort Silver ($ZSL) is trending as traders aggressively position for a significant correction in silver, widely viewed as overextended after its recent strong rally. The community is actively debating the sustainability of silver's gains, with many utilizing this inverse ETF as a direct bearish bet or to hedge existing precious metal holdings against anticipated market shifts.

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Coupang Inc - Ordinary Shares - Class A

Coupang Inc 

Coupang (CPNG) is trending due to significant fallout from a major data breach, which has prompted a CEO resignation and ongoing government investigations, including police searches and potential large-scale lawsuits. Community sentiment reflects strong concern over the company's handling of the incident and its implications for consumer trust and business operations in South Korea, its primary market.

Bitwise 10 Crypto Index ETF - Common Shares Of Beneficial Interest

Bitwise 10 Crypto Index Fund

Bitwise 10 Crypto Index Fund is actively discussed amid a polarized crypto market, with strong bearish voices predicting a prolonged "crypto winter" while bullish investors point to increasing institutional adoption and positive fund inflows into the sector. A significant talking point for BITW is its notable trading discount to Net Asset Value, which the community anticipates could narrow as the fund progresses with its regulatory efforts to convert to an Exchange Traded Product. This potential structural change creates an arbitrage opportunity, driving conversation among those monitoring the fund's correlation to Bitcoin and other major digital assets.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending following its recent earnings report, which showcased revenue growth and an emphasized focus on providing essential on-site power for the surging AI-driven data center market. The community is actively discussing the potential for major contract conversions from their extensive pipeline of megawatts, with many viewing the company's natural gas-fueled solutions as a timely answer to the energy demands of hyperscalers, distinguishing it from other fuel cell players. This narrative, coupled with efforts to scale manufacturing and improve financials, fuels optimism for its path toward future profitability despite past challenges.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is trending amid news of its integration-ready post-quantum vault, enhancing its security. The community is actively discussing BCH's surprising resilience and outperformance compared to Bitcoin and other altcoins during a challenging market. Many believe it is significantly undervalued and poised for a major breakout, with speculation of large institutional interest driving this potential decoupling from broader market trends.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is generating significant buzz as investors anticipate its merger with quantum technology firm Infleqtion, fueled by recent bullish commentary from Citron Research. Community sentiment views Infleqtion as a highly undervalued leader in the quantum sector, differentiated by its real revenue, critical defense contracts for GPS-denied navigation, and advanced neutral-atom technology.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu is currently trending as its dedicated "Wolfpack" community actively promotes the recently launched WolfSwap, a cross-chain swap aggregator focused on utility and decentralization. The community is heavily discussing the project's potential as a leading memecoin, often drawing comparisons to early Shiba Inu, and highlighting its consistent trending presence across platforms. Many believe Sailana is building something unique and urge others not to overlook its ongoing development and future innovations planned for 2026.

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Speculation surrounding a potential SpaceX IPO is driving significant buzz across the aerospace sector, with community attention intensely focused on "SpaceX IPO plays." Among these, $MNTS is trending due to its partnership with SpaceX, serving as a critical payload deployment provider for upcoming Falcon 9 missions, including high-profile DoD and commercial satellites. Its notably low total share count and recent contract awards are fueling comparisons to past explosive "meme stock" movements, making it a prominent talking point among investors seeking indirect exposure to the surging space market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stock Index Futures Climb on Trump Tariffs Report, U.S. PPI Data and Fed Speak in Focus

March S&P 500 E-Mini futures (ESH25) are up +0.49%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.67% this morning as a report indicating the U.S. might take a gradual approach to hiking tariffs boosted sentiment, while investors awaited crucial producer inflation data and comments from Federal Reserve officials.

Intra-Cellular Therapies' stock (ITCI) surged over 35% in premarket trading on Monday, poised for its best-ever open and a record high, even as broader market futures grappled with weak tech stock performance.&nbsp;The biotech firm announced it would be acquired by Johnson &amp; Johnson (JNJ) in a $14.6 billion cash deal, valuing ITCI shares at $132 each,&nbsp;which represents about 40% premium to previous close.The transaction, funded through a mix of cash and debt, is expected to close later this year, subject to shareholder and regulatory approvals. Once completed, ITCI shares will be delisted from the Nasdaq.&nbsp;Johnson &amp; Johnson plans to maintain its capital allocation strategy, including R&amp;D investment, dividends, and strategic share buybacks.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ITCI_sentiment_and_message_volume_Jan_13_premarket_42a2cd35bb.png" alt="ITCI sentiment and message volume Jan 13 premarket.png" width="1318" height="324"><figcaption>ITCI sentiment and message volume Jan 13 premarket as of 7:40 am ET | source: Stocktwits</figcaption></figure>Following the announcement, sentiment for ITCI on Stocktwits turned 'extremely bullish,' and the stock became one of the platform's top 20 trending symbols.&nbsp;Some retail investors speculated that J&amp;J secured a bargain deal amid a flurry of positive chatter.<stembedurl>https://stocktwits.com/manymore/message/599736216</stembedurl><stembedurl>https://stocktwits.com/megamaven/message/599767133</stembedurl>Shares of J&amp;J, meanwhile, were flat premarket Monday following a more than 2% dip over the last week, with retail sentiment on Stocktwits turning 'bullish.’ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million in 2023.The company recently reached a favorable patent settlement with Sandoz, ensuring no generic Caplyta will launch until 2040. Analysts at BofA Securities raised ITCI's price target to $118 on Sunday, citing the settlement's positive implications.<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/32a4bb19-5f28-4ea7-a9c8-a776ef2fecd9">According</a> to the Financial Times, the deal highlights J&amp;J's strategic response to looming patent cliffs, including its projected $17 billion revenue loss when its Darzalex treatment for rare blood cancers loses exclusivity in 2029.The report added that the acquisition marks a bright spot for the biotech sector, which saw M&amp;A activity plunge in 2024. Pharma companies spent $45 billion across 30 deals — nearly half the prior year's total.ITCI stock gained 12.7% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism

ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million in 2023.

Equity

J&J explores takeover bid for Intra-Cellular Therapies, Bloomberg reports

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

ITCI
Intra-Cellular Therapies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ITCI News

ITCIIntra-Cellular Therapies Inc